Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Key claim: A phase II trial is evaluating whether the combination of ruxolitinib phosphate and azacytidine is an effective treatment for patients with myelofibrosis or MDS/MPN overlap neoplasms.
Abstract
This phase II trial studies how well ruxolitinib phosphate and azacytidine work in treating patients with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacytidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ruxolitinib phosphate and azacytidine may be an effective treatment for myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm.
Why this matters
MDS/MPN overlap syndromes and MF share both proliferative and (often) dysplastic features, and prospective therapeutic evidence for the overlap category is scarce. Co-enrolling both populations in a phase II ruxolitinib + azacytidine trial tests whether a JAK inhibitor + hypomethylating agent backbone can serve as a unifying regimen across these biologically related but distinct subtypes, and may inform whether transformation-prone or dysplastic MF subsets benefit similarly to MDS/MPN-overlap patients.